Rigel appoints veteran commercial executive Michael P. Miller to drive growth initiatives

Rigel taps veteran commercial executive to drive growth initiatives

Rigel Pharmaceuticals appoints Michael P. Miller to its board of directors, bolstering commercial capacity as the South San Francisco biotech advances its marketed medicines and development pipeline. The company announces the appointment on Feb. 3, 2026 via PR Newswire, saying Miller’s more than four decades of commercial and leadership experience will support Rigel’s strategic plan to grow its existing portfolio and evaluate in‑licensing opportunities.

Rigel’s president and chief executive Raul Rodriguez says Miller’s “commercial execution expertise” directly aligns with the company’s transformational objectives, particularly expanding patient access and maximizing revenue from current products. Miller joins with recent board roles at Puma Biotechnology and BioXcel Therapeutics and a track record leading U.S. commercial operations at Jazz Pharmaceuticals, where he serves most recently as executive vice president, U.S. commercial until retiring in 2020. Rigel frames the hire as a step to strengthen commercialization as it balances marketed products with clinical and discovery-stage programs.

Miller says he is “thrilled to join Rigel as a Director,” noting that he sees the company as a profitable operation with a “strong commercial engine” capable of funding a promising development pipeline. His experience overseeing oncology and specialty medicine franchises — including roles at Genentech, Vivus, Connetics (later acquired), ALZA, and Syntex — positions him to advise on market launches, lifecycle management and potential partnerships or in‑licensing deals aimed at hematologic disorders and cancer.

Pipeline and portfolio focus

Founded in 1996, Rigel markets products and advances a pipeline of potential therapies targeting hematologic disorders and oncology. The company uses commercial revenues to support development programs and is emphasizing strategic opportunities that can expand its therapeutic reach and patient impact.

Sector relevance and strategic context

The appointment underscores a broader industry trend where mid‑sized biotech firms seek seasoned commercial leaders to translate clinical assets into sustainable businesses. Rigel’s move reflects the need for commercialization expertise to optimize launches, negotiate partnerships and evaluate deals that can accelerate access to novel therapies.